Literature DB >> 2398267

Gastric mucosal prostaglandin E2 levels in cirrhosis and portal hypertension.

H Weiler1, C Weiler, W Gerok.   

Abstract

Prostaglandin E2 (PGE2) tissue levels were measured, using radioimmunoassay, in specimens from the gastric antral mucosa in (a) healthy subjects, (b) patients without liver diseases in the absence or presence of gastric ulcers, and (c) patients with alcoholic cirrhosis in the absence or presence of gastric ulcers. These groups were divided further into subgroups with or without portal hypertension. PGE2 tissue levels in subjects without liver diseases were not significantly different from those of cirrhotic patients without portal hypertension. However, in cirrhotic patients with portal hypertension, the PGE2 content was significantly lower, especially in the presence of congestion in the mucosa (about 70-80%). When a gastric antral ulcer was present, a further statistically significant decrease of the PGE2 levels was observed. It was concluded that a decrease in the PGE2 tissue levels in the gastric mucosa of cirrhotic patients is related to the presence of portal hypertension. Congestion in the mucosa, as a pathogenetically relevant factor for mucosal PGE2 deficiency, may play a role.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2398267     DOI: 10.1016/0168-8278(90)90272-s

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  10 in total

Review 1.  Portal hypertensive gastropathy and gastric antral vascular ectasia (GAVE) syndrome.

Authors:  K W Burak; S S Lee; P L Beck
Journal:  Gut       Date:  2001-12       Impact factor: 23.059

2.  Portal hypertensive gastropathy: A systematic review of the pathophysiology, clinical presentation, natural history and therapy.

Authors:  Mihajlo Gjeorgjievski; Mitchell S Cappell
Journal:  World J Hepatol       Date:  2016-02-08

3.  Cytoprotective activity in the gastric mucosa of rats exposed to carbon tetrachloride-induced liver injury.

Authors:  O Bulbena; J Culat; M L Bravo
Journal:  Inflammation       Date:  1997-10       Impact factor: 4.092

4.  Gastric mucosal PGE2 levels in gastric non-ulcer and ulcer patients with chronic renal failure or without renal diseases and in healthy subjects.

Authors:  H Weiler; C Weiler; W Gerok
Journal:  Dig Dis Sci       Date:  1990-12       Impact factor: 3.199

5.  Prostaglandin E2 and prostaglandin F2 alpha biosynthesis in human gastric mucosa: effect of chronic alcohol misuse.

Authors:  C Bode; G Maute; J C Bode
Journal:  Gut       Date:  1996-09       Impact factor: 23.059

6.  Taurocholate induced gastric mucosal injuries in experimental portal hypertension.

Authors:  W J Angerson; J G Geraghty; D C Carter
Journal:  Gut       Date:  1992-02       Impact factor: 23.059

7.  Peptic ulcer surgery in patients with liver cirrhosis.

Authors:  T Lehnert; C Herfarth
Journal:  Ann Surg       Date:  1993-04       Impact factor: 12.969

8.  Maintenance of intragastric pH > 4 with famotidine in duodenal ulcer patients: factors influencing drug requirements.

Authors:  J C Delchier; F Roudot-Thoraval; L Stanescu; M C Deharvengt; L Elouaer Blanc
Journal:  Gut       Date:  1994-06       Impact factor: 23.059

9.  The recurrent bleeding risk of a Forrest IIc lesion at the second-look endoscopy can be indicated by high Rockall scores ≥ 6.

Authors:  Er-Hsiang Yang; Chung-Tai Wu; Hsin-Yu Kuo; Wei-Ying Chen; Bor-Shyang Sheu; Hsiu-Chi Cheng
Journal:  Surg Endosc       Date:  2019-06-20       Impact factor: 4.584

10.  Role of ascitic prostaglandin E2 in diagnosis of spontaneous bacterial peritonitis and prediction of in-hospital mortality in patients with decompensated cirrhosis.

Authors:  Junli Luo; Xianmei Wu; Yu Zhang; Wenxiang Huang; Bei Jia
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.